Clinical trial
TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections
NCT00023413 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections
- Lead sponsor
- Centers for Disease Control and Prevention
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 1999
- Completion date
- February 29, 2004
- Enrollment
- 20
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.